AK MEDICAL (01789) has released its interim results for the 2026 fiscal year, posting a revenue of approximately HK$765 million, reflecting a year-on-year increase of 10.2%.

The company's profit attributable to equity shareholders reached around HK$197 million, up 22.5% compared to the same period last year, with earnings per share standing at HK$0.1768.

According to the announcement, the revenue growth was primarily driven by significant increases in overseas market sales and smart device sales.

The notable rise in profit was mainly attributed to the revenue expansion, coupled with an improved gross margin resulting from a higher proportion of overseas and digital orthopaedic products, as well as smart device sales, which carry relatively higher margins.